143 related articles for article (PubMed ID: 8726839)
1. Liver cell adenoma in a young man with elevated serum PIVKA-II level.
Uto H; Shigehira M; Kawano T; Nagatomo H; Kuribayashi T; Taniguchi S; Koga K; Komada N; Kitamura T; Maruyama T; Tsubouchi H
J Gastroenterol; 1996 Jun; 31(3):441-5. PubMed ID: 8726839
[TBL] [Abstract][Full Text] [Related]
2. Liver cell adenoma with malignant transformation: a case report.
Ito M; Sasaki M; Wen CY; Nakashima M; Ueki T; Ishibashi H; Yano M; Kage M; Kojiro M
World J Gastroenterol; 2003 Oct; 9(10):2379-81. PubMed ID: 14562419
[TBL] [Abstract][Full Text] [Related]
3. Clinical evaluation of plasma des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes.
Kasahara A; Hayashi N; Fusamoto H; Kawada Y; Imai Y; Yamamoto H; Hayashi E; Ogihara T; Kamada T
Dig Dis Sci; 1993 Dec; 38(12):2170-6. PubMed ID: 7505217
[TBL] [Abstract][Full Text] [Related]
4. Plasma abnormal prothrombin (PIVKA-II): a new and reliable marker for the detection of hepatocellular carcinoma.
Takikawa Y; Suzuki K; Yamazaki K; Goto T; Madarame T; Miura Y; Yoshida T; Kashiwabara T; Sato S
J Gastroenterol Hepatol; 1992; 7(1):1-6. PubMed ID: 1371940
[TBL] [Abstract][Full Text] [Related]
5. Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Comparison with alpha-fetoprotein.
Suehiro T; Sugimachi K; Matsumata T; Itasaka H; Taketomi A; Maeda T
Cancer; 1994 May; 73(10):2464-71. PubMed ID: 7513601
[TBL] [Abstract][Full Text] [Related]
6. Acarboxy prothrombin (PIVKA-II) as a marker of hepatoblastoma in infants.
Motohara K; Endo F; Matsuda I; Iwamasa T
J Pediatr Gastroenterol Nutr; 1987; 6(1):42-5. PubMed ID: 2432210
[TBL] [Abstract][Full Text] [Related]
7. Abnormal prothrombin (DES-gamma-carboxy prothrombin) in hepatocellular carcinoma.
Nakao A; Virji A; Iwaki Y; Carr B; Iwatsuki S; Starzl E
Hepatogastroenterology; 1991 Oct; 38(5):450-3. PubMed ID: 1722483
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory Hepatocellular Adenoma with Elevated Serum Protein Induced by Vitamin K Absence/Antagonist-II in Adult Males.
Koya Y; Suzuki T; Tai M; Ichii O; Matsuhashi N; Ejiri Y; Miyazawa M; Shibata M; Harada M; Kumabe T; Nakashima O
Intern Med; 2019 Jun; 58(12):1739-1746. PubMed ID: 30799343
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of ED036 kit for measuring serum PIVKA-II levels in small hepatocellular carcinoma.
Kuromatsu R; Tanaka M; Shimauchi Y; Shimada M; Tanikawa K; Watanabe K; Yokoo T
J Gastroenterol; 1997 Aug; 32(4):507-12. PubMed ID: 9250899
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic analysis of stage II-III hepatocellular carcinoma showing early massive recurrence after liver resection.
Yamanaka J; Yamanaka N; Nakasho K; Tanaka T; Ando T; Yasui C; Kuroda N; Takata M; Maeda S; Matsushita K; Uematsu K; Okamoto E
J Gastroenterol Hepatol; 2000 Oct; 15(10):1192-8. PubMed ID: 11106101
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous resection of liver cell adenomas and an intrahepatic portosystemic venous shunt with elevation of serum PIVKA-II level.
Seyama Y; Sano K; Tang W; Kokudo N; Sakamoto Y; Imamura H; Makuuchi M
J Gastroenterol; 2006 Sep; 41(9):909-12. PubMed ID: 17048056
[TBL] [Abstract][Full Text] [Related]
12. Abnormal prothrombin: evaluation as a tumour marker and localization in tissues of patients with hepatocellular carcinoma.
Koda T; Yamazaki S; Tamura I; Nakaba H; Takao T; Katayama S; Kurimura O
J Gastroenterol Hepatol; 1993; 8(3):212-6. PubMed ID: 7686054
[TBL] [Abstract][Full Text] [Related]
13. [Clinical usefulness of plasma PIVKA-II assay and its limitations in patients with hepatocellular carcinoma].
Fujiyama S; Morishita T; Shibata J; Sato T
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1129-38. PubMed ID: 2471453
[TBL] [Abstract][Full Text] [Related]
14. Mediastinal Yolk Sac Tumor Producing Protein Induced by Vitamin K Absence or Antagonist-II.
Akutsu N; Adachi Y; Isosaka M; Mita H; Takagi H; Sasaki S; Yamamoto H; Arimura Y; Ishii Y; Masumori N; Endo T; Shinomura Y
Intern Med; 2015; 54(12):1531-6. PubMed ID: 26073245
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical studies of PIVKA-II in hepatocellular carcinoma by indirect immunofluorescence.
Kuwahara N; Higashi T; Nouso K; Ito T; Tsuji T
Acta Med Okayama; 1995 Feb; 49(1):19-24. PubMed ID: 7762405
[TBL] [Abstract][Full Text] [Related]
16. Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis.
Caviglia GP; Ribaldone DG; Abate ML; Ciancio A; Pellicano R; Smedile A; Saracco GM
Scand J Gastroenterol; 2018 Jun; 53(6):734-740. PubMed ID: 29667463
[TBL] [Abstract][Full Text] [Related]
17. Clinical evaluation of a monoclonal antibody to serum KM01 for the diagnosis of hepatocellular carcinoma.
Fujii T; Horie Y; Ikuta Y; Nishimuki E; Murawaki Y; Suou T; Kawasaki H
Clin Chim Acta; 1995 Apr; 236(1):71-9. PubMed ID: 7545092
[TBL] [Abstract][Full Text] [Related]
18. Abnormal plasma prothrombin (PIVKA-II) levels in hepatocellular carcinoma.
Kawaguchi Y
Jpn J Surg; 1989 May; 19(3):296-300. PubMed ID: 2550692
[TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of serum alpha-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist-II (PIVKA-II) levels in patients with hepatocellular carcinoma following interventional radiology.
Minakuchi K; Murata K; Kaminoh T; Takada K; Takashima S; Nakamura K; Onoyama Y
Radiat Med; 1993; 11(6):231-6. PubMed ID: 7512271
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic significance of protein induced vitamin K absence or antagonist II and alpha-fetoprotein in hepatocellular carcinoma.
Nakagawa T; Seki T; Shiro T; Wakabayashi M; Imamura M; Itoh T; Tamai T; Nishimura A; Yamashiki N; Matsuzaki K; Sakaida N; Inoue K; Okamura A
Int J Oncol; 1999 Feb; 14(2):281-6. PubMed ID: 9917503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
